ORMP Stock Price, Oramed Pharmaceuticals Quote, Chart

Market Summary

USD2.30-0.03

Delayed

-1.29%

ORMP Stock Price

View Fullscreen

ORMP RSI Chart

ORMP Valuation

Market Cap

93.4M

Price/Earnings (Trailing)

8.85

Price/Sales (Trailing)

69.74

EV/EBITDA

-9.42

Price/Free Cashflow

-14.88

ORMP Price/Sales (Trailing)

ORMP Profitability

Operating Margin

93.28%

EBT Margin

-760.00%

Return on Equity

6.37%

Return on Assets

5.19%

Free Cashflow Yield

-6.72%

ORMP Fundamentals

ORMP Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ORMP Earnings

Earnings (TTM)

10.6M

Earnings Growth (Yr)

142.54%

Earnings Growth (Qtr)

-88.57%

Breaking Down ORMP Revenue

Last 7 days

-4.2%

Last 30 days

-1.3%

Last 90 days

-26.7%

Trailing 12 Months

-44.0%

How does ORMP drawdown profile look like?

ORMP Financial Health

Current Ratio

5.28

ORMP Investor Care

Shares Dilution (1Y)

1.50%

Diluted EPS (TTM)

0.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.8M	4.9M	3.1M	1.3M
2022	2.8M	2.5M	2.5M	1.7M
2021	2.9M	2.9M	2.7M	2.8M
2020	2.7M	2.7M	2.7M	2.7M
2019	2.6M	2.6M	2.7M	2.7M
2018	2.5M	2.5M	2.4M	2.5M
2017	1.5M	2.0M	2.5M	2.5M
2016	0	0	641.0K	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oramed Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	reznick yehuda	acquired	-	-	29,800	-
Jan 30, 2024	aghion daniel	acquired	-	-	3,750	-
Jan 04, 2024	silberman david	acquired	-	-	136,500	chief financial officer
Jan 04, 2024	aghion daniel	acquired	-	-	35,070	-
Jan 04, 2024	shapiro benjamin	acquired	-	-	35,070	-
Jan 04, 2024	sank leonard	acquired	-	-	39,325	-
Jan 04, 2024	kidron nadav	acquired	-	-	329,000	president and ceo
Jan 04, 2024	kidron miriam	acquired	-	-	295,500	chief scientific officer
Jan 04, 2024	hexter joshua	acquired	-	-	180,500	coo & cbo
Jan 04, 2024	mayer arie	acquired	-	-	39,325	-

Which funds bought or sold ORMP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Beacon Capital Management, LLC	unchanged	-	67.00	639	-%
May 16, 2024	Murchinson Ltd.	added	31.38	1,602,620	4,028,120	0.34%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-9.52	31,712	252,359	-%
May 15, 2024	Mariner, LLC	new	-	30,788	30,788	-%
May 15, 2024	STATE STREET CORP	added	0.27	35,825	169,745	-%
May 15, 2024	MORGAN STANLEY	reduced	-30.41	-17,849	130,550	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	5.77	211,251	838,192	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	9,000	39,000	-%
May 15, 2024	LM Advisors LLC	sold off	-100	-5,775	-	-%
May 15, 2024	Tyler-Stone Wealth Management	unchanged	-	183	876	-%

Are Funds Buying or Selling ORMP?

Are funds buying ORMP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORMP

No. of Funds

Unveiling Oramed Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2024	kidron nadav	5.7%	2,343,919	SC 13D
Sep 02, 2021	kidron nadav	4.1%	1,343,446	SC 13D/A
Feb 09, 2021	slager david mark	5.04%	1,344,123	SC 13G/A
Feb 14, 2020	altium capital management lp	4.99%	972,000	SC 13G/A
Feb 11, 2020	slager david mark	7.4%	1,316,323	SC 13G
Jan 21, 2020	sabby management, llc	4.99%	885,015	SC 13G/A

Recent SEC filings of Oramed Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 18, 2024	4	Insider Trading
Apr 02, 2024	3	Insider Trading
Mar 22, 2024	SC 13D	13D - Major Acquisition
Mar 19, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	424B5	Prospectus Filed

Peers (Alternatives to Oramed Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Oramed Pharmaceuticals Inc News

Latest updates

Oramed Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2
Revenue	-	-	-	1,239,000	2,478,000	1,597,000	158,000	682,000	350,000	544,000	904,000	674,000	682,000	678,000	674,000	681,000	666,000	665,000	904,000	674,000	681,000	681,000
S&GA Expenses	-100.0%	-	8,712,000	-663,000	192,000	184,000	12,378,000	463,000	380,000	590,000	898,000	585,000	172,000	1,050,000	1,926,000	1,297,000	-	1,664,000	-	727,000	730,000	1,030,000
R&D Expenses	-33.2%	1,179,000	1,766,000	957,000	1,821,000	4,427,000	9,037,000	5,347,000	9,179,000	5,836,000	9,037,000	6,410,000	6,086,000	8,872,000	3,198,000	5,502,000	6,168,000	3,869,000	6,889,000	5,774,000	2,968,000	1,925,000
EBITDA Margin	0%	-5.93	-5.93	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	592,000	-	826,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	2,558,000	308,000	-	100,000	617,000	122,000	128,000	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-100.0%	-	13,296,000	-3,284,000	-	-	-13,043,000	-7,153,000	-	-	-	-	-7,536,000	-	-	-5,625,000	-	-4,608,000	-	-	-2,996,000	-2,284,000
EBT Margin	0%	-7.60	-7.60	-9.92	-6.79	-11.97	-19.24	-10.05	-8.40	-7.41	-7.47	-7.53	-7.60	-5.73	-5.78	-5.32	-4.67	-	-	-	-	-
Net Income	-88.6%	1,536,000	13,444,000	-3,222,000	-1,194,000	-3,611,000	-12,255,000	-7,060,000	-10,533,000	-10,708,000	-12,255,000	-8,098,000	-7,536,000	-10,413,500	-3,909,000	-5,207,000	-6,063,000	-4,608,000	-7,324,000	-5,570,000	-2,996,000	-2,284,000
Net Income Margin	95.0%	7.88	4.04	-6.49	-4.91	-12.01	-23.39	-16.35	-16.83	-13.76	-13.78	-10.87	-9.90	-9.45	-7.37	-7.96	-8.10	-	-	-	-	-
Free Cashflow	-4.0%	-1,478,000	-1,421,000	-726,000	-2,654,000	-5,748,000	-8,370,000	-2,362,000	-8,510,000	-9,172,000	-11,131,000	-7,214,000	-9,460,000	-9,460,000	-3,709,000	-3,709,000	-3,709,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Assets	-7.7%	204	221	231	156	160	162	164	162	172	178	182	128	80.00	62.00	41.00	45.00	46.00	30.00	31.00	35.00	37.00
Current Assets	8.9%	177	163	176	151	155	157	160	135	144	148	152	95.00	72.00	57.00	36.00	41.00	41.00	29.00	31.00	33.00	27.00
Cash Equivalents	105.1%	19.00	9.00	5.00	7.00	24.00	40.00	33.00	30.00	28.00	27.00	32.00	77.00	57.00	34.00	15.00	19.00	9.00	6.00	3.00	3.00	-
Net PPE	-6.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	-36.9%	34.00	53.00	78.00	1.00	5.00	6.00	7.00	6.00	6.00	7.00	8.00	7.00	6.00	6.00	6.00	5.00	4.00	5.00	5.00	5.00	5.00
Short Term Borrowings	-37.2%	32.00	51.00	75.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	1.2%	166	164	149	151	150	152	153	153	162	167	170	117	68.00	49.00	28.00	33.00	34.00	16.00	17.00	19.00	-
Retained Earnings	1.0%	-156	-157	-170	-167	-166	-163	-154	-147	-136	-126	-122	-114	-108	-102	-98.18	-92.61	-89.62	-87.33	-83.65	-81.10	-78.82
Additional Paid-In Capital	0.4%	322	321	320	319	317	314	308	301	299	293	292	230	176	152	126	125	123	103	101	100	100
Shares Outstanding	0.4%	41.00	40.00	40.00	40.00	40.00	40.00	39.00	39.00	39.00	38.00	38.00	28.00	31.00	-	-	-	-	-	-	-	-
Minority Interest	1.1%	-0.92	-0.93	-0.90	-0.89	-0.82	-0.66	-0.66	-0.66	-0.13	0.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	131	-	-	-	170	-	-	-	-	-	228	-	-	-	61.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-4.1%	-1,476	-1,418	-694	-2,634	-5,549	-8,062	-2,241	-8,490	-9,125	-11,122	-6,903	-	-9,149	-	-	-3,682	-1,138	-8,263	-6,152	-2,458	-3,357
Share Based Compensation	-5.3%	1,294	1,367	852	1,820	173	2,548	3,050	1,882	4,029	1,776	-	-	985	-	982	-	411	-	317	-423	319
Cashflow From Investing	0.0%	29,998	29,997	-75,122	-14,710	-13,203	11,260	1,229	10,363	7,359	-99,248	-99,048	-	-43,311	-	-	10,753	294	-2,405	1,199	10,963	-13,237
Cashflow From Financing	24.0%	-19,000	-25,000	74,548	-	2,430	4,175	4,313	-1.00	2,292	60,572	60,563	-	16,308	-	-	29,032	13,012	13,001	586	1,478	19,979

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ORMP Income Statement

2024-03-31

Interim Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
REVENUES		$ 666
RESEARCH AND DEVELOPMENT EXPENSES	(1,179)	(4,427)
SALES AND MARKETING EXPENSES		(184)
GENERAL AND ADMINISTRATIVE EXPENSES	(1,783)	(1,263)
OPERATING LOSS	(2,962)	(5,208)
INTEREST EXPENSES	(592)
FINANCIAL INCOME, NET	5,088	1,597
NET INCOME (LOSS)	1,534	(3,611)
NET INCOME (LOSS) ATTRIBUTABLE TO NON-CONTROLLING INTERESTS	(2)	(216)
NET INCOME (LOSS) ATTRIBUTABLE TO STOCKHOLDERS	$ 1,536	$ (3,395)
BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 0.04	$ (0.08)
DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 0.04	$ (0.08)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	40,835,953	40,041,258
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	41,564,007	40,041,258

ORMP Balance Sheet

2024-03-31

Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 18,576	$ 9,055
Short-term deposits	80,285	95,279
Investments at fair value	77,733	57,713
Prepaid expenses and other current assets	501	537
Total current assets	177,095	162,584
LONG-TERM ASSETS:
Long-term deposits	7	7
Investments at fair value	19,544	51,035
Marketable securities	2,026	1,807
Other non-marketable equity securities	3,524	3,524
Amounts funded in respect of employee rights upon retirement	29	27
Property and equipment, net	819	873
Operating lease right-of-use assets	608	694
Total long-term assets	26,557	57,967
Total assets	203,652	220,551
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,267	1,609
Short-term borrowings	32,034	51,013
Payable to related parties	1	325
Operating lease liabilities	254	267
Total current liabilities	33,556	53,214
LONG-TERM LIABILITIES:
Long-term deferred revenues	4,000	4,000
Employee rights upon retirement	29	28
Provision for uncertain tax position	11	11
Operating lease liabilities	272	342
Other liabilities	63	63
Total long-term liabilities	4,375	4,444
COMMITMENTS (note 3)
EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS:
Common stock, $0.012 par value (60,000,000 authorized shares; 40,519,160 and 40,338,979 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)	487	485
Additional paid-in capital	322,172	320,892
Accumulated deficit	(156,020)	(157,556)
Total stockholders’ equity	166,639	163,821
Non-controlling interests	(918)	(928)
Total equity	165,721	162,893
Total liabilities and equity	$ 203,652	$ 220,551

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

0

CEO	Mr. Nadav Kidron Esq.
WEBSITE	oramed.com
INDUSTRY	Biotechnology

Oramed Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Oramed Pharmaceuticals Inc? What does ORMP stand for in stocks?

ORMP is the stock ticker symbol of Oramed Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oramed Pharmaceuticals Inc (ORMP)?

As of Fri May 17 2024, market cap of Oramed Pharmaceuticals Inc is 93.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORMP stock?

You can check ORMP's fair value in chart for subscribers.

What is the fair value of ORMP stock?

You can check ORMP's fair value in chart for subscribers. The fair value of Oramed Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oramed Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORMP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oramed Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ORMP is over valued or under valued. Whether Oramed Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Oramed Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORMP.

What is Oramed Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ORMP's PE ratio (Price to Earnings) is 8.85 and Price to Sales (PS) ratio is 69.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oramed Pharmaceuticals Inc's stock?

In the past 10 years, Oramed Pharmaceuticals Inc has provided -0.132 (multiply by 100 for percentage) rate of return.